copyright
lee
et
al
openaccess
articl
distribut
term
creativ
common
attribut
licens
cc
permit
unrestrict
use
distribut
reproduct
medium
provid
origin
author
sourc
credit
gemcitabin
anticanc
chemotherapi
drug
addit
shown
antivir
activ
broad
rang
virus
also
previous
report
synergist
antivir
activ
ribavirin
enterovirus
cytidin
analog
gemcitabin
report
inhibitori
activ
pyrimidin
biosynthesi
addit
inhibitor
pyrimidin
biosynthesi
shown
induc
innat
immun
yettobedetermin
manner
inhibit
viru
infect
thu
also
investig
whether
antienterovir
activ
gemcitabin
mediat
innat
immun
induct
relat
inhibit
pyrimidin
synthesi
studi
found
addit
exogen
cytidin
uridin
uridin
monophosph
ump
effect
revers
antivir
activ
gemcitabin
enterovirusinfect
well
enterovir
repliconharbor
cell
demonstr
gemcitabin
target
salvag
pathway
moreov
express
sever
interferon
ifn
stimul
gene
isg
significantli
induc
treatment
gemcitabin
also
suppress
cotreat
cytidin
result
suggest
antivir
activ
gemcitabin
involv
isg
induc
inhibit
pyrimidin
biosynthesi
enterovirus
belong
picornavirida
famili
character
singl
strand
positivesens
rna
genom
nucleotid
emerg
major
caus
agent
variou
human
diseas
coxsackieviru
one
wellstudi
enterovirus
caus
viral
mening
myocard
pancreat
addit
enteroviru
caus
agent
handfootmouth
diseas
also
sever
neurolog
symptom
lead
even
death
howev
despit
increas
public
threat
effect
therapi
current
avail
treatment
infect
enterovirus
hundr
distinct
virus
newli
emerg
enterovirus
increasingli
report
recent
year
moreov
mani
rna
virus
includ
influenza
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
zika
viru
zikv
becom
enorm
threat
public
health
therefor
broadspectrum
antivir
drug
necessari
effici
control
variou
viral
infect
anoth
aspect
ineffect
convent
enzymetarget
drug
due
rapid
develop
resist
mutant
anoth
hurdl
need
tackl
order
achiev
develop
broadspectrum
antivir
drug
low
rate
mutat
two
strategi
gener
consid
one
target
host
cellular
factor
essenti
requir
viral
life
cycl
strategi
would
low
potenti
produc
resist
virus
undesir
side
effect
could
accompani
activ
innat
immun
respons
interferon
ifn
signal
boost
host
antivir
defens
system
actual
ifn
combin
antivir
drug
ribavirin
primarili
use
treatment
variou
rna
viru
infect
recent
inhibitor
nucleosid
biosynthesi
shown
induc
innat
immun
suppress
broad
rang
viru
infect
instanc
wang
et
al
identifi
broadspectrum
antivir
compound
brequinar
target
dhodh
key
enzym
pyrimidin
biosynthet
pathway
subsequ
induc
innat
immun
respons
previous
identifi
gemcitabin
drug
current
use
anticanc
chemotherapi
effect
inhibitor
enterovirus
includ
human
rhinovirus
hrv
antivir
activ
also
shown
variou
rna
virus
includ
hepat
c
viru
hcv
human
immunodefici
viru
hiv
influenza
viru
polioviru
merscov
zikv
gemcitabin
cytidin
analog
report
interfer
pyrimidin
biosynthesi
howev
role
pyrimidin
inhibit
involv
subsequ
innat
immun
antivir
action
gemcitabin
explor
yet
studi
examin
role
pyrimidin
inhibit
antivir
activ
gemcitabin
ad
exogen
nucleosid
repliconharbor
hela
cell
result
antivir
effect
gemcitabin
remark
suppress
pyrimidin
nucleosid
analysi
demonstr
gemcitabin
inhibit
salvag
pathway
pyrimidin
biosynthet
pathway
probabl
target
cytidin
andor
uridin
synthesi
moreov
treatment
gemcitabin
activ
express
sever
ifnstimul
gene
isg
major
effector
innat
immun
also
suppress
supplement
cytidin
previous
identifi
new
indic
gemcitabin
effect
antienterovir
inhibitor
cytidin
analog
gemcitabin
known
inhibitori
activ
pyrimidin
biosynthesi
besid
inhibitor
pyrimidin
biosynthesi
report
show
antivir
activ
least
partli
activ
innat
immun
respons
thu
studi
sought
examin
antienterovir
activ
gemcitabin
also
associ
modul
pyrimidin
biosynthesi
innat
immun
first
order
test
antienterovir
activ
gemcitabin
relat
inhibit
pyrimidin
biosynthesi
hela
cell
infect
simultan
treat
excess
nucleosid
adenosin
guanosin
uridin
cytidin
presenc
variou
dose
gemcitabin
hour
antivir
activ
measur
stain
infect
cell
antibodi
secondari
antibodi
conjug
fluoresc
dye
count
cell
fluoresc
signal
previous
report
gemcitabin
exhibit
strong
antivir
activ
infect
estim
ic
maxim
efficaci
figur
gemcitabin
cotreat
excess
nucleosid
two
pyrimidin
nucleosid
cytidin
uridin
could
significantli
suppress
antivir
activ
gemcitabin
result
sustain
infect
especi
cytidin
strongest
effect
explain
fact
gemcitabin
cytidin
analog
effect
cytidin
evid
demonstr
dosedepend
suppress
gemcitabin
antivir
activ
supplementari
figur
contrast
purin
nucleosid
adenosin
guanosin
littl
effect
control
experi
cell
viabil
analyz
condit
use
mtt
assay
figur
littl
chang
except
treatment
adenosin
without
gemcitabin
decreas
cell
viabil
indic
cytotox
effect
adenosin
phenomenon
confirm
independ
experi
use
increas
concentr
nucleosid
without
infect
supplementari
figur
confirm
effect
pyrimidin
nucleosid
antivir
activ
gemcitabin
subgenom
replicon
system
addit
use
system
contain
firefli
luciferas
gene
place
structur
gene
viral
genom
allow
quantit
measur
viral
replic
hela
cell
transfect
vitrotranscrib
replicon
rna
simultan
treat
nucleosid
presenc
variou
dose
gemcitabin
hour
similar
result
infect
experi
figur
addit
excess
pyrimidin
nucleosid
cytidin
uridin
remark
suppress
antivir
activ
gemcitabin
therebi
protect
replic
replicon
supplementari
figur
accord
previou
studi
gemcitabin
strong
antivir
effect
well
therefor
also
test
pyrimidin
nucleosid
replicon
system
result
cytidin
uridin
suppress
antivir
activ
gemcitabin
replic
replicon
similar
observ
assay
supplementari
figur
collect
result
strongli
indic
involv
pyrimidin
biosynthesi
antivir
activ
gemcitabin
observ
antivir
effect
gemcitabin
suppress
supplement
pyrimidin
nucleosid
direct
us
defin
effect
gemcitabin
pyrimidin
biosynthet
pathway
pyrimidin
biosynthesi
occur
two
separ
pathway
de
novo
synthesi
salvag
figur
determin
pathway
step
affect
gemcitabin
intermedi
pathway
test
dihydroorot
dho
orot
acid
use
intermedi
de
novo
biosynthet
pathway
nucleobas
adenin
guanin
uracil
cytosin
addit
use
intermedi
salvag
pathway
uridin
monophosph
ump
act
downstream
pathway
also
includ
ump
synthes
uridin
uridin
kinas
salvag
pathway
separ
orotidin
monophosph
omp
omp
decarboxylas
de
novo
biosynthet
pathway
figur
gemcitabin
nucleosid
analog
may
directli
affect
activ
enzym
involv
pyrimidin
biosynthesi
result
decreas
intermedi
act
downstream
target
thu
excess
addit
intermedi
act
downstream
gemcitabin
target
rescu
deficit
supposedli
show
suppress
effect
antivir
activ
gemcitabin
select
intermedi
cotreat
gemcitabin
hela
cell
ump
significantli
show
suppress
effect
extent
similar
cytidin
figur
intermedi
de
novo
pathway
dho
orot
acid
salvag
pathway
nucleobas
margin
effect
condit
littl
chang
cell
viabil
shown
figur
moreov
similar
effect
ump
also
observ
repliconharbor
cell
supplementari
figur
even
though
slightli
weaker
cytidin
taken
togeth
result
figur
seem
gemcitabin
majorli
target
salvag
pathway
rather
de
novo
pathway
particularli
uridin
andor
cytidin
synthesi
uracil
andor
cytosin
figur
antivir
compound
interf
nucleosid
biosynthesi
subsequ
induc
innat
immun
involv
upregul
isg
studi
antivir
compound
induc
express
ifnstimul
respons
element
isr
luciferas
report
even
without
ifn
stimul
thu
also
examin
gemcitabin
stimulatori
effect
isreluciferas
report
hela
cell
transfect
report
plasmid
treat
gemcitabin
ngml
hour
hour
posttreat
gemcitabin
increas
luciferas
activ
control
figur
increas
luciferas
activ
much
evid
hour
posttreat
maxim
reach
control
figur
contrast
induc
luciferas
express
control
hour
posttreat
respect
indic
rapid
stimul
figur
gemcitabin
significantli
stimul
isr
promot
appar
differ
timekinet
isr
promot
slowli
respond
gemcitabin
compar
differenti
mechan
isr
activ
gemcitabin
propos
discuss
section
confirm
isr
activ
gemcitabin
correl
antivir
activ
test
antivir
activ
enhanc
longer
treatment
gemcitabin
hela
cell
treat
gemcitabin
hour
prior
infect
maintain
anoth
hour
achiev
hour
treatment
exposur
antivir
activ
assess
quantifi
virusinfect
cell
show
fluoresc
signal
protein
hour
treatment
gemcitabin
result
consider
stronger
antivir
effect
exhibit
longer
time
treatment
exposur
shorter
time
treatment
exposur
supplementari
figur
estim
ic
gemcitabin
exposur
cell
much
lower
exposur
cell
moreov
maximum
efficaci
gemcitabin
exposur
cell
appar
higher
exposur
cell
result
indic
enhanc
antivir
activ
longer
exposur
cell
gemcitabin
like
correl
stronger
activ
isr
promot
attain
hour
treatment
ifn
trigger
intracellular
signal
jak
stat
pathway
transcript
induc
numer
isg
control
isr
accord
aforement
result
gemcitabin
stimulatori
effect
isr
promot
like
ifn
howev
mode
activ
seem
quit
differ
thu
order
confirm
activ
isrecontain
promot
gemcitabin
know
differ
promot
respond
gemcitabin
transcript
express
isg
analyz
hela
cell
treat
increas
dose
gemcitabin
hour
total
rna
prepar
quantit
realtim
pcr
result
gemcitabin
strongli
induc
two
gene
ump
pyrimidin
biosynthet
pathway
treat
describ
figur
figur
b
cytidin
use
posit
control
averag
standard
deviat
obtain
three
independ
experi
indic
p
c
pyrimidin
biosynthet
pathway
test
metabolit
indic
box
metabolit
signific
effect
shown
orang
box
salvag
pathway
affect
gemcitabin
depict
blue
arrow
control
moder
three
gene
less
control
figur
hand
strongli
induc
isg
control
figur
result
indic
gemcitabin
differ
mode
isg
activ
order
confirm
whether
isg
activ
gemcitabin
mediat
modul
pyrimidin
biosynthesi
test
effect
cytidin
activ
gene
two
strongest
respond
gemcitabin
expect
supplement
cytidin
consider
suppress
gemcitabineinduc
express
figur
contrast
cytidin
signific
effect
ifninduc
express
clarifi
whether
stimul
innat
immun
respons
gemcitabin
independ
ifninduc
jakstat
pathway
first
examin
phosphoryl
tyr
major
event
occur
earli
step
ifn
signal
hela
cell
treat
variou
dose
gemcitabin
hour
hour
cell
lysat
analyz
western
blot
result
level
phosphoryl
protein
chang
gemcitabin
hour
treatment
supplementari
figur
contrari
treatment
remark
increas
phosphoryl
protein
time
condit
supplementari
figur
expect
addit
examin
whether
gemcitabineinduc
isg
express
involv
form
ifnstimul
gene
factor
complex
interact
phosphoryl
function
transcript
activ
isg
sirnamedi
knockdown
affect
gemcitabineinduc
express
signific
reduc
effect
induc
decreas
control
supplementari
figur
collect
result
demonstr
antivir
effect
gemcitabin
involv
activ
isg
mode
differ
ifndepend
convent
way
mediat
least
partli
inhibit
pyrimidin
biosynthesi
discuss
gemcitabin
current
use
cancer
therapi
antivir
activ
broad
rang
rna
virus
includ
polioviru
hcv
influenza
merscov
zikv
previou
studi
also
identifi
gemcitabin
effect
potent
antienterovir
agent
herein
defin
underli
mechan
gemcitabin
antivir
action
involv
modul
pyrimidin
biosynthesi
subsequ
activ
isg
accumul
report
nucleosid
analog
act
antivir
agent
modul
nucleotid
biosynthesi
cytidin
analog
gemcitabin
also
expect
work
way
inde
antivir
activ
gemcitabin
repliconharbor
hela
cell
significantli
suppress
addit
exogen
pyrimidin
nucleosid
cytidin
uridin
purin
nucleosid
figur
supplementari
figur
delin
demonstr
gemcitabin
act
salvag
pathway
rather
de
novo
pathway
target
probabl
uridin
andor
cytidin
synthesi
uracil
andor
cytosin
figur
supplementari
figur
therefor
conceiv
gemcitabin
induc
decreas
pyrimidin
nucleosid
subsequ
metabolit
includ
ump
report
inhibit
pyrimidin
biosynthesi
induc
innat
immun
respons
especi
activ
isg
major
antivir
mechan
earli
stage
viru
infect
previou
find
confirm
test
observ
activ
isr
promot
leflunomid
inhibitor
dihydroorot
dehydrogenas
dhodh
pyrimidin
biosynthet
pathway
supplementari
figur
importantli
newli
reveal
gemcitabin
also
activ
isr
promot
figur
activ
isr
promot
gemcitabin
confirm
signific
induct
endogen
isg
test
evalu
quantit
realtim
pcr
analysi
figur
intriguingli
increas
mrna
particularli
outstand
increas
mrna
definit
suppress
addit
treatment
cytidin
suggest
role
antivir
effect
gemcitabin
famili
member
among
highli
induc
isg
respons
ifn
mani
report
concern
antivir
function
variou
virus
instanc
protein
exhibit
antivir
effect
gener
sequestr
viral
genom
also
inhibit
hcv
translat
initi
bind
requir
effici
ribosom
recruit
hcv
ire
addit
ifit
target
hpv
helicas
essenti
viral
dna
replic
report
antihuman
papillomaviru
hpv
effect
ifit
protein
isg
strongli
stimul
gemcitabin
encod
retino
acidinduc
gene
rigi
part
rigilik
receptor
famili
function
pattern
recognit
receptor
sensor
singleor
doublestrand
rna
virus
flaviviru
influenza
reoviru
involv
trigger
antivir
respons
also
ifit
protein
may
majorli
contribut
antivir
action
gemcitabin
way
similar
aforement
mechan
still
would
exclud
contribut
isg
untest
isg
effector
full
antivir
activ
gemcitabin
one
interest
observ
studi
gemcitabin
seem
activ
express
isg
way
differ
first
isr
promot
slowli
respond
gemcitabin
compar
figur
gemcitabin
weakli
activ
isr
promot
hour
almost
fulli
hour
treatment
quit
contrari
achiev
full
activ
even
hour
treatment
second
pattern
isg
activ
quit
differ
gemcitabin
figur
gemcitabin
exhibit
rel
strong
induct
mrna
mrna
similarli
strong
stimulatori
effect
mrna
consid
isg
contain
element
promot
mode
gemcitabin
seem
weakli
depend
independ
contrari
highli
depend
third
phosphoryl
tyr
induc
gemcitabin
remark
induct
phosphoryl
observ
supplementari
figur
fourth
express
mrna
induc
gemcitabin
affect
sirnamedi
knockdown
contrari
result
express
mrna
significantli
reduc
condit
supplementari
figur
fifth
gemcitabineinduc
express
mrna
significantli
suppress
addit
treatment
cytidin
affect
figur
observ
particular
signific
strongli
suggest
crosstalk
pyrimidin
biosynthesi
innat
immun
respons
induc
gemcitabin
decreas
pyrimidin
pool
inactiv
metabol
enzym
might
trigger
signal
deliv
certain
cisact
element
subset
isg
possibl
relay
kinas
mention
signal
less
like
depend
ifnstimul
gene
factor
major
transcript
complex
ifninduc
jakstat
pathway
rather
possibl
role
need
altern
evalu
investig
follow
studi
clarifi
underli
molecular
mechan
gemcitabin
antivir
action
result
particularli
suppress
gemcitabineinduc
isg
activ
cytidin
figur
indic
gemcitabineinduc
innat
immun
respons
mediat
least
partli
pyrimidinedeplet
effect
moreov
accord
result
figur
gemcitabin
pyrimidinedeplet
effect
seem
occur
mainli
target
salvag
pathway
howev
consid
neither
excess
cytidin
uridin
ump
could
achiev
full
suppress
gemcitabin
antivir
effect
dmso
control
figur
seem
way
contribut
account
residu
portion
antivir
effect
besid
salvag
pathway
pyrimidin
biosynthesi
gemcitabin
known
inhibit
ribonucleotid
reductas
catalyz
format
dntp
ntp
anoth
caus
nucleotid
deplet
thu
residu
antivir
activ
might
explain
addit
inhibit
nucleotid
biosynthesi
seemingli
result
sever
nucleotid
deplet
subsequ
stronger
isg
activ
altern
gemcitabin
could
incorpor
newli
synthes
viral
genom
directli
inhibit
rdrp
activ
result
reduc
viral
replic
studi
demonstr
involv
pyrimidin
inhibitioninduc
innat
immun
respons
antivir
activ
gemcitabin
particularli
target
salvag
pathway
antivir
action
gemcitabin
innat
immun
support
feasibl
therapeut
applic
broadspectrum
antivir
drug
hela
cell
purchas
atcc
cultur
previous
describ
stock
nanci
atcc
also
purchas
atcc
amplifi
hela
cell
gemcitabin
nucleosid
adenosin
guanosin
cytidin
uridin
nucleobas
adenin
guanin
cytosin
uracil
pyrimidin
synthet
intermedi
dihydroorot
dho
orot
acid
uridin
monophosph
ump
leflunomid
purchas
sigmaaldrich
rabbit
polyclon
antibodi
gener
hous
immun
recombin
protein
antirabbit
secondari
antibodi
conjug
alexa
fluor
purchas
life
technolog
examin
involv
pyrimidin
biosynthet
pathway
antivir
activ
gemcitabin
hela
cell
infect
moi
simultan
treat
nucleosid
nucleobas
pyrimidin
biosynthet
intermedi
hour
postinfect
cell
fix
icecold
mixtur
methanolaceton
vv
wash
twice
pb
infect
cell
stain
rabbit
polyclon
antibodi
antirabbit
secondari
antibodi
conjug
nuclei
counterstain
hoechst
life
technolog
imag
captur
viral
infect
quantifi
previous
describ
infect
calcul
percentag
rel
dmso
control
mtt
assay
use
measur
cell
viabil
describ
previous
cell
viabil
calcul
percentag
rel
control
plasmid
contain
firefli
luciferas
gene
place
capsid
code
region
viral
genom
kindli
provid
frank
j
van
kuppeveld
utrecht
univers
netherland
synthesi
replicon
rna
replicon
assay
perform
previous
describ
briefli
hela
cell
cellswel
plate
transfect
replicon
rna
split
plate
cellswel
simultan
treat
nucleosid
nucleobas
pyrimidin
biosynthet
intermedi
presenc
gemcitabin
eight
hour
compound
treatment
cell
assay
firefli
luciferas
activ
use
oneglo
luciferas
assay
system
promega
hela
cell
cellswel
plate
transfect
isreluciferas
report
plasmid
use
lipofectamin
invitrogen
split
plate
cellswel
ifnstimul
respons
element
isr
luciferas
report
plasmid
describ
previous
fortyeight
hour
transfect
cell
treat
gemcitabin
anoth
hour
thereaft
cell
assay
firefli
luciferas
activ
use
oneglo
luciferas
assay
system
promega
total
rna
cell
treat
compound
plate
prepar
use
rneasi
mini
kit
qiagen
cdna
gener
use
superscript
iv
life
technolog
random
hexam
quantif
isg
express
perform
realtim
pcr
use
ssofast
evagreen
supermix
biorad
primer
describ
previou
report
mrna
also
quantifi
use
endogen
control
hela
cell
cellswel
plate
treat
gemcitabin
hour
cell
lysat
prepar
subject
western
blot
analysi
tyr
antibodi
gapdh
protein
also
analyz
load
control
detail
procedur
describ
previous
tyr
antibodi
purchas
cell
signal
technolog
gapdh
antibodi
purchas
santa
cruz
biotechnolog
hela
cell
cellswel
plate
transfect
neg
control
sirna
use
lipofectamin
rnaimax
reagent
invitrogen
hour
treat
gemcitabin
anoth
hour
thereaft
total
rna
prepar
analyz
quantit
realtim
pcr
mrna
sirna
synthes
bioneer
daejeon
south
korea
figur
data
present
mean
standard
deviat
obtain
independ
experi
repres
p
p
p
respect
analyz
student
ttest
author
declar
conflict
interest
